Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma.
B7‐H3
anaplastic meningioma
chimeric antigen receptor
immunotherapy
Journal
Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
11
2019
revised:
01
04
2020
accepted:
21
04
2020
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
18
6
2020
Statut:
epublish
Résumé
We conducted a first-in-human study to evaluate the bioactivity and safety of B7-H3-targeted chimeric antigen receptor (CAR) autologous T cells for treating recurrent anaplastic meningioma. Tumor tissues from a patient with recurrent anaplastic meningioma were evaluated for B7-H3 expression. B7-H3-targeted CAR-T cells were delivered into the intracranial tumor resection cavity using an Ommaya device at a maximum dose of 1.5 × 10 Immunochemical analysis demonstrated high and homogeneous B7-H3 expression in tumor samples. MRI results indicated that the tumor near the delivery device was relatively stable compared with the rapid progression of tumors distant from the device. We found CAR-T-cell trafficking to regions of B7-H3 Our results suggested that although intracavitary administration of B7-H3-targeted CAR-T cells was safe and resulted in local bioactivity, addressing antigen loss and CAR-T-cell trafficking may further enhance the applications of B7-H3-targeted CAR-T-cell therapy.
Identifiants
pubmed: 32547742
doi: 10.1002/cti2.1137
pii: CTI21137
pmc: PMC7292833
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e1137Informations de copyright
© 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology Inc.
Déclaration de conflit d'intérêts
Aiping Tong, Gang Guo and Liangxue Zhou filed a patent for the mAb, scFv and CAR targeting B7‐H3. Other authors declare no competing interests.
Références
Int J Hematol. 2014 Apr;99(4):361-71
pubmed: 24311149
J Neurooncol. 2017 Jun;133(2):321-330
pubmed: 28429237
J Neurooncol. 2013 Feb;111(3):257-64
pubmed: 23232807
J Immunol. 2004 Feb 15;172(4):2352-9
pubmed: 14764704
Clin Cancer Res. 2015 Sep 15;21(18):4062-72
pubmed: 26059190
Oncologist. 2020 Jan;25(1):e138-e146
pubmed: 31585984
Clin Cancer Res. 2019 Apr 15;25(8):2560-2574
pubmed: 30655315
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
Neurosurg Clin N Am. 2016 Apr;27(2):239-47
pubmed: 27012388
Oncol Lett. 2015 Oct;10(4):2204-2208
pubmed: 26622819
Mol Ther Oncolytics. 2019 Jul 23;14:279-287
pubmed: 31485480
Clin Cancer Res. 2010 Oct 1;16(19):4892-8
pubmed: 20719934
Blood. 2014 Apr 24;123(17):2625-35
pubmed: 24578504
Annu Rev Med. 2017 Jan 14;68:139-152
pubmed: 27860544
Cancer Cell. 2017 Apr 10;31(4):501-515.e8
pubmed: 28399408
Nat Rev Neurol. 2018 Feb;14(2):106-115
pubmed: 29302064
Clin Cancer Res. 2008 Aug 15;14(16):5150-7
pubmed: 18694993
J Neurooncol. 2010 Sep;99(3):307-14
pubmed: 20821343
Cancer Cell. 2019 Feb 11;35(2):221-237.e8
pubmed: 30753824
Sci Transl Med. 2017 Jul 19;9(399):
pubmed: 28724573